Premium
THE EFFECTS OF DIFFERENT DOSE REGIMES OF D‐SER(TBU) 6 ‐LHRH‐EA 10 (HOE 766) IN SUBJECTS WITH HYPOGONADOTROPHIC HYPOGONADISM
Author(s) -
MOORE M. P.,
SMITH R.,
DONALD R. A.,
ESPINER E. A.,
STRONACH S.
Publication year - 1981
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1981.tb00369.x
Subject(s) - hypogonadotrophic hypogonadism , microgram , medicine , endocrinology , basal (medicine) , testosterone (patch) , hypogonadotropic hypogonadism , steroid , hormone , chemistry , insulin , in vitro , biochemistry
SUMMARY Eight male patients with hypogonadotrophic hypogonadism were treated with injections of a long acting LHRH analogue, HOE 766. Six of the patients were on daily subcutaneous injections of 5 μ g of this analogue at the start of this study and were changed to alternate‐daily injections of the same dose for 1–3 months. They were then treated with twice‐daily injections of 0·5 μ g HOE 766, as was another subject not previously treated. The HOE 766 twice‐daily was given alone for 1 or 2 months and then sex steroid replacement therapy was added to this for a further 4–5 months. There was no clinical improvement or rise in plasma testosterone levels until sex steroid therapy was commenced. Basal LH and FSH levels and peak responses to 100 μ g LHRH remained low throughout the study. It is concluded that these variations in dose and interval of administration do not overcome the lack of pituitary response which is a feature of prolonged treatment with LHRH analogues.